- Home
- BCAB vs LGVN Comparison
BCAB vs LGVN Comparison
Compare BCAB & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- LGVN
- Stock Information
- Founded
- BCAB 2007
- LGVN 2014
- Country
- BCAB United States
- LGVN United States
- Employees
- BCAB N/A
- LGVN N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- BCAB Health Care
- LGVN Health Care
- Exchange
- BCAB Nasdaq
- LGVN Nasdaq
- Market Cap
- BCAB 28.6M
- LGVN 25.2M
- IPO Year
- BCAB 2020
- LGVN 2021
- Fundamental
- Price
- BCAB $0.46
- LGVN $1.52
- Analyst Decision
- BCAB Buy
- LGVN Strong Buy
- Analyst Count
- BCAB 2
- LGVN 3
- Target Price
- BCAB $5.00
- LGVN $8.67
- AVG Volume (30 Days)
- BCAB 990.6K
- LGVN 251.2K
- Earning Date
- BCAB 03-25-2025
- LGVN 02-25-2025
- Dividend Yield
- BCAB N/A
- LGVN N/A
- EPS Growth
- BCAB N/A
- LGVN N/A
- EPS
- BCAB N/A
- LGVN N/A
- Revenue
- BCAB $11,000,000.00
- LGVN $1,852,000.00
- Revenue This Year
- BCAB N/A
- LGVN $208.32
- Revenue Next Year
- BCAB N/A
- LGVN $43.96
- P/E Ratio
- BCAB N/A
- LGVN N/A
- Revenue Growth
- BCAB N/A
- LGVN 141.46
- 52 Week Low
- BCAB $0.43
- LGVN $0.77
- 52 Week High
- BCAB $4.02
- LGVN $6.40
- Technical
- Relative Strength Index (RSI)
- BCAB 23.28
- LGVN 33.10
- Support Level
- BCAB $0.46
- LGVN $1.52
- Resistance Level
- BCAB $0.49
- LGVN $1.65
- Average True Range (ATR)
- BCAB 0.04
- LGVN 0.11
- MACD
- BCAB 0.03
- LGVN -0.02
- Stochastic Oscillator
- BCAB 27.98
- LGVN 17.65
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.